Related Experiment Video
Updated: Jul 27, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic
Hua Bai1, Wen-Hui Wang1, Fan-Fan Zhou1
1Department of Oncology, People's Hospital of Zhengzhou, Zhengzhou, People's Republic of China.
Objective:
Therapeutic regimens are relatively scarce among patients with treatment-refractory metastatic colorectal cancer (CRC). This study aimed to determine the feasibility and tolerability of anlotinib plus PD-1 blockades in patients with treatment-refractory metastatic CRC retrospectively.
Methods:
A total of 68 patients with previously treated metastatic CRC who received anlotinib plus PD-1 blockades in clinical practice were included in this study retrospectively. Demographic and clinical characteristics of the patients, therapeutic outcomes and safety profile during administration were collected and briefly analyzed. All subjects were followed up regularly. Therapeutic outcomes, including drug response and prognosis, were presented, and a safety profile was depicted to illustrate the adverse reactions.
Results:
A total of 68 patients with treatment-refractory metastatic CRC who received anlotinib plus PD-1 blockades in clinical practice were included in the final analysis. Best therapeutic response during treatment indicated that partial response was observed in 11 patients, stable disease was noted in 41 patients, and progressive disease was found in 16 patients, producing an objective response rate of 16.2% (95% CI: 8.4%-27.1%) and a disease control rate of 76.5% (95% CI: 64.6%-85.9%). Prognostic analysis suggested that the median progression-free survival (PFS) of the 68 patients was 5.3 months (95% CI: 3.01-7.59), and the median overall survival (OS) was 12.5 months (95% CI: 9.40-15.60). Of the 11 patients who responded, the median duration of response was 6.7 months (95% CI: 2.89-10.53). Safety profile during treatment showed that patients experienced adverse reactions regardless of grade, and grade ≥3 adverse reactions were found in 61 patients (89.7%) and 41 patients (60.3%), respectively. Common adverse reactions were hypertension, myelosuppression (including leukopenia, neutropenia, thrombocytopenia, and anemia), fatigue, and hand-foot syndrome.
Conclusion:
Anlotinib plus PD-1 blockades demonstrated encouraging efficacy and acceptable safety profile in patients with treatment-refractory metastatic CRC preliminarily in clinical practice. This conclusion should be confirmed in prospective clinical trials.
Insights
Anlotinib combined with PD-1 blockade shows preliminary efficacy in refractory metastatic colorectal cancer (CRC). This combination therapy offers a potential new option for patients with limited treatment choices, warranting further investigation.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic colorectal cancer (CRC) presents limited therapeutic options for patients refractory to standard treatments.
- Identifying novel treatment strategies is crucial for improving outcomes in advanced CRC.
Purpose of the Study:
- To evaluate the feasibility and tolerability of anlotinib plus PD-1 blockade in patients with treatment-refractory metastatic CRC.
- To assess the therapeutic outcomes and safety profile of this combination regimen in a real-world clinical setting.
Main Methods:
- Retrospective analysis of 68 patients with previously treated metastatic CRC who received anlotinib plus PD-1 blockade.
- Collection and analysis of demographic, clinical characteristics, therapeutic outcomes, and adverse events.
- Regular follow-up to monitor drug response, prognosis, and safety profile.
Main Results:
- Objective response rate (ORR) was 16.2% and disease control rate (DCR) was 76.5%.
- Median progression-free survival (PFS) was 5.3 months and median overall survival (OS) was 12.5 months.
- High incidence of grade ≥3 adverse reactions (89.7%), with common toxicities including hypertension, myelosuppression, fatigue, and hand-foot syndrome.
Conclusions:
- Anlotinib plus PD-1 blockade demonstrates preliminary encouraging efficacy and an acceptable safety profile in patients with treatment-refractory metastatic CRC.
- Further confirmation through prospective clinical trials is recommended to validate these findings.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
